Renalytix plc, a precision medicine diagnostics company focussed on kidney disease, has raised £10.1 million in a share placing.

It has also issued conversion shares to Heights Capital Management Inc at the issue price of 6p, increasing the transaction value to £13.6m.

Renalytix’s official HQ is in London, with operational teams based in the US.